Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School, discusses findings from the phase 3 TiNivo-2 trial (NCT04987203) investigating tivozanib (Fotivda) plus nivolumab (Opdivo) vs tivozanib monotherapy in patients with metastatic renal cell carcinoma (RCC) who had previously progressed on or after an immune checkpoint inhibitor (ICI).